<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396498</url>
  </required_header>
  <id_info>
    <org_study_id>TDCCC005</org_study_id>
    <nct_id>NCT02396498</nct_id>
  </id_info>
  <brief_title>SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy</brief_title>
  <official_title>S-1 With Cisplatin Intravenous Chemotherapy Versus S-1 Plus Cisplatin Hyperthermic Intraperitoneal Chemotherapy in Stage Ⅲ Patients After D2 Gastrectomy：a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tang-Du Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the safety and efficacy of S-1 plus cisplatin hyperthermic
      intraperitoneal chemotherapy in stage Ⅲ patients after D2 gastrectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized clinical trial，and subjects wuill be assigned two arms: SP
      Intravenous Chemotherapy or SP by HIPEC .After 8 cycles treatment,we assess the safety and
      efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS: Disease-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the date of random to the date of recurrence or death for disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS: Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the date of random to the date of death or to the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>The subjects should finish the quality of life scale by themselves before treament in every cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by Adverse Events and Serious Adverse events In the process of the total treatment according CTCAE4.0</measure>
    <time_frame>6 months</time_frame>
    <description>record and collect subjects' AE and SAE In the process of the total treatment according CTCAE4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Stage Ⅲ Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>D2 radical gastrectomy+Systemic chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 cycles of systemic chemotherapy were performed for stage Ⅲ patients after D2 gastrectomy .Systemic chemotherapy(SP): Cisplatin: 60mg/m^2, d1 , Intravenous infusion, every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks .Subjects should be given maximum 8 cycles, or progression/intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2 radical gastrectomy+HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after D2 radical gastrectomy. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>Using cisplatin in HIPEC plus oral S-1</description>
    <arm_group_label>D2 radical gastrectomy+HIPEC</arm_group_label>
    <other_name>hyperthermic intraperitoneal chemoperfusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 ≤ age ≤ 70 years old

          -  Histologically diagnosed as stageⅢ gastric adenocarcinoma，and perform D2 radical
             gastrectomy，as well as have not received any Anti-tumor
             therapy：chemotherapy,biological treatment or molecular targeted therapy , etc.

          -  The Eastern Cooperative Oncology Group (ECOG) status ≤ 2

          -  Having given written informed consent prior to any procedure related to the study

          -  Expected survival time ≥3 months

        Exclusion Criteria:

          -  History of severe hypersensitivity reactions to the ingredients of S-1 or Cisplatin

          -  Hemoglobin＜90g/L

          -  Inadequate hematopoietic function which is defined as below:

               -  white blood cell (WBC) less than 3,500/mm^3

               -  absolute neutrophil count (ANC) less than 1,500/mm^3

               -  platelets less than 80,000/mm^3

          -  Inadequate hepatic or renal function which is defined as below:

               -  serum bilirubin greater than 2 times the upper limit of normal range

               -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than
                  2.5 times the ULN if no demonstrable liver metastases or greater than 5 times the
                  ULN in the presence of liver metastases

               -  blood creatinine level greater than 1.5 times ULN,Creatinine clearance&lt;60ml/min

          -  Receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine drug

          -  Women who is pregnant or lactating or fertile women of child-bearing potential unless
             using a reliable and appropriate contraceptive method throughout the treatment period
             (Including male)

          -  Psychiatric disorder or symptom that makes participation of the patient difficult

          -  Myocardial infarction, existing serious or unstable angina, and patients with cardiac
             insufficiency in 6 months

          -  Severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed
             interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure,
             poorly-controlled diabetes

          -  Known DPD deficiency

          -  Participate in other clinical trial before the start of this trial

          -  Patient compliance is bad or researchers believe that patients are not suitable for
             this treatment

          -  Known to have active hepatitis patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helong Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tang-Du Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helong Zhang, Professor</last_name>
    <phone>029-87777225</phone>
    <email>cnxazhl@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IEC of Insititution for National Drug Clinical Trials,Tangdu Hospital,Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Liu</last_name>
      <phone>029-84777631</phone>
      <email>tangduec@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

